#USA #New York #Rosen Law Firm #Jasper Therapeutics #JSPR

Class Action Lawsuit Against Jasper Therapeutics, Inc.

On September 27, 2025, the Rosen Law Firm, a prominent global investor rights organization, announced the launch of a class action lawsuit targeting Jasper Therapeutics, Inc. (NASDAQ: JSPR). This lawsuit concerns investors who acquired securities between November 30, 2023, and July 3, 2025—a period during which multiple disclosures raised questions about the company’s operations and regulatory compliance.

Background of the Case

The lawsuit alleges that Jasper Therapeutics made a series of misleading statements regarding their operational practices and product manufacturing standards. Specifically, they reportedly failed to establish adequate controls necessary to ensure that their third-party manufacturers adhered to current Good Manufacturing Practice (cGMP) regulations. This oversight likely compromised the quality of their clinical trial products, notably briquilimab.

As a consequence of these violations, it is asserted that Jasper overstated both the clinical and commercial potential of their offerings, thus misleading investors about the company's financial health and operational risks. Following the revelation of these truths, investor confidence plummeted, leading to considerable financial damages for those affected.

How to Get Involved

Investors who purchased securities during the stated class period and wish to participate in this class action are encouraged to take action. They can also reach out directly to Phillip Kim, Esq. at the Rosen Law Firm via their toll-free number 866-767-3653 or email for additional information. It is important for interested parties to act quickly, as the deadline to become a lead plaintiff is set for November 18, 2025. The lead plaintiff will serve as a representative for all class members in the proceedings.

Why Select Rosen Law Firm?

The Rosen Law Firm has built a stellar reputation in handling securities class actions, characterized by an extensive track record of successful settlements. Notably, they secured the largest securities class action settlement at the time against a Chinese company. Their expertise has continually placed them among the top law firms for securities litigation. In 2017, they were ranked number one by ISS Securities Class Action Services for their settlements, and they have succeeded in recovering substantial sums for investors in past litigations, including over $438 million in 2019 alone.

Key Issues and Allegations

The central allegations of this lawsuit include:

• - Jasper’s failure to maintain sufficient controls and procedures for third-party manufacturers.
• - The potential negative impact of this failure on ongoing study results and regulatory prospects.
• - Increased likelihood of disruptive measures affecting operational costs.

These points highlight systemic issues within the company that may have ultimately misled investors as to their financial viability and product integrity.

Next Steps for Investors

It’s essential to note that, at this stage, no class has been certified, meaning that investors wishing to participate are encouraged to seek individual counsel or retain representation. The ability to share in any potential future recovery does not hinge on becoming a lead plaintiff, allowing for more flexible options depending on each individual's circumstances.

For ongoing updates regarding the lawsuit and other relevant information, investors are invited to follow the Rosen Law Firm on various social media platforms, ensuring they remain informed throughout the legal proceedings.

Conclusion

The filing of this class action lawsuit against Jasper Therapeutics, Inc. represents a significant opportunity for aggrieved investors to seek redress for potential losses incurred due to alleged securities fraud. As details continue to unfold, the legal team at Rosen Law Firm remains poised to advocate for the rights of injured investors, paving the way for accountability within corporate structures that affect shareholder interests.